{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:50:07Z","timestamp":1773892207272,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>The rapid outbreak of Coronavirus Disease 2019 (COVID-19) that was first identified in Wuhan, China is caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The 3CL protease (3CLpro) is the main protease of the SARS-CoV-2, which is responsible for the viral replication and therefore considered as an attractive drug target since to date there is no specific and effective vaccine available against this virus. In this paper, we reported molecular docking-based virtual screening (VS) of 2000 compounds obtained from the ZINC database and 10 FDA-approved (antiviral and anti-malaria) on 3CLpro using AutoDock Vina to find potential inhibitors. The screening results showed that the top four compounds, namely ZINC32960814, ZINC12006217, ZINC03231196, and ZINC33173588 exhibited high affinity at the 3CLpro binding pocket. Their free energy of binding (FEB) were \u221212.3, \u221211.9, \u221211.7, and \u221211.2 kcal\/mol while AutoDock Vina scores were \u221212.61, \u221212.32, \u221212.01, and -11.92 kcal\/mol, respectively. These results were better than the co-crystallized ligand N3, whereby its FEB was \u22127.5 kcal\/mol and FDA-approved drugs. Different but stable interactions were obtained between the four identified compounds with the catalytic dyad residues of the 3CLpro. In conclusion, novel 3CLpro inhibitors from the ZINC database were successfully identified using VS and molecular docking approach, fulfilling the Lipinski rule of five, and having low FEB and functional molecular interactions with the target protein. The findings suggests that the identified compounds may serve as potential leads that act as COVID-19 3CLpro inhibitors, worthy for further evaluation and development.<\/jats:p>","DOI":"10.3389\/fmolb.2020.603037","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T06:59:50Z","timestamp":1608274790000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening"],"prefix":"10.3389","volume":"7","author":[{"given":"Ashraf Ahmed Ali","family":"Abdusalam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikneswaran","family":"Murugaiyah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/emboj\/cdg005","article-title":"Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site.","volume":"22","author":"Bourne","year":"2003","journal-title":"EMBO J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/978-1-4939-7000-1_26","article-title":"Protein data bank (PDB): the single global macromolecular structure archive.","volume":"1607","author":"Burley","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset.","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings.","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.","volume":"55","author":"Colson","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses.","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses.","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein\u2013ligand docking and virtual drug screening with the AutoDock suite.","volume":"11","author":"Forli","year":"2016","journal-title":"Nat. Protoc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1021\/jm030596b","article-title":"Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 3. The free energy contribution of structural water molecules in HIV-1 protease complexes.","volume":"47","author":"Fornabaio","year":"2004","journal-title":"J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/v12020135","article-title":"Return of the Coronavirus: (2019)-nCoV.","volume":"12","author":"Granlinski","year":"2020","journal-title":"Viruses"},{"key":"B12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan.","volume":"395","author":"Huang","year":"2020","journal-title":"China. Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714%2B","article-title":"ZINC- a free database of commercially available compounds for virtual screening.","volume":"45","author":"Irwin","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: a free tool to discover chemistry for biology.","volume":"52","author":"Irwin","year":"2012","journal-title":"J. Chem. Inf. Modell."},{"key":"B15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.parco.2007.02.010","article-title":"Virtual screening on large scale grids.","volume":"33","author":"Jacq","year":"2007","journal-title":"Parallel Comput."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.26.964882","article-title":"Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19.","author":"Jin","year":"","journal-title":"bioRxiv [Preprint]"},{"key":"B17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M pro from SARS-CoV-2 and discovery of its inhibitors.","volume":"582","author":"Jin","year":"","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"LigPlot+: multiple ligand\u2013protein interaction diagrams for drug discovery.","volume":"51","author":"Laskowski","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.2174\/09298673113209990001","article-title":"Virtual screening strategies in drug discovery: a critical review.","volume":"20","author":"Lavecchia","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jmb.2005.09.004","article-title":"Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide.","volume":"353","author":"Lee","year":"2005","journal-title":"J. Mol. Biol."},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.36877\/pddbs.a0000065","article-title":"Computational screening and identifying binding interaction of anti-viral and anti-malarial drugs: toward the potential cure for SARS-CoV-2.","volume":"3","author":"Lee","year":"2020","journal-title":"Prog. Drug Discov. Biomed. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead-and drug-like compounds: the rule-of-five revolution.","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.cbpa.2007.08.033","article-title":"Virtual screening strategies in drug discovery.","volume":"11","author":"McInnes","year":"2007","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility.","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrmicro2147","article-title":"Coronaviruses post-SARS: update on replication and pathogenesis.","volume":"7","author":"Perlman","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"B27","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study.","volume":"9","author":"Que","year":"2003","journal-title":"Hong Kong Med. J."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2020.101578","article-title":"Going global-travel and the 2019 novel coronavirus.","volume":"33","author":"Rodr\u00edguez-Morales","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"B29","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/pr.112.007336","article-title":"Computational methods in drug discovery.","volume":"66","author":"Sliwoski","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/prot.10504","article-title":"Docking studies and model development of tea polyphenol proteasome inhibitors: applications to rational drug design.","volume":"54","author":"Smith","year":"2004","journal-title":"Proteins"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19.","volume":"177","author":"Touret","year":"2020","journal-title":"Antiviral Res."},{"key":"B32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"B34","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration.","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"B35","year":"","journal-title":"Novel Coronavirus (2019-nCoV)."},{"key":"B36","year":"","journal-title":"WHO Situation Report -23."},{"key":"B37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China.","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/v12020244","article-title":"Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV.","volume":"12","author":"Xu","year":"2020","journal-title":"Viruses"},{"key":"B39","doi-asserted-by":"publisher","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor.","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B40","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijid.2020.01.050","article-title":"Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak.","volume":"92","author":"Zhao","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1582-4934.2008.00665.x","article-title":"Docking, virtual high throughput screening and in silico fragment-based drug design.","volume":"13","author":"Zoete","year":"2009","journal-title":"J. Cell Mol. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses\u2014drug discovery and therapeutic options.","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2020.603037\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T06:41:54Z","timestamp":1698475314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2020.603037\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,17]]},"references-count":42,"alternative-id":["10.3389\/fmolb.2020.603037"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2020.603037","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,17]]},"article-number":"603037"}}